Rishi Puri
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Rishi Puri has a total of 90 co-authors. Here are the top co-authors by number of shared publications:
- Ari M. Melnick
Josep Carreras Leukaemia Research Institute, Barcelona, Spain
26 shared publications - Ahmet Dogan
Memorial Sloan Kettering Cancer Center, New York, NY
25 shared publications - Alireza Karbalayghareh
Computational and Systems Biology Program, Memorial Sloan Kettering Cancer Center, New York, USA
25 shared publications - Amos Fong
British Columbia Cancer 6 Vancouver, British Columbia
25 shared publications - Amy Chadburn
Weill Cornell Medicine 13 New York, NY
25 shared publications - Benedikt W. Pelzer
Weill Cornell Medicine 2 New York City
25 shared publications
Latest Publications
- Open Access
Establishment of Patient-Derived Xenotransplant and Cell Line Models for Canine B-Cell Lymphoma
High-grade canine B-cell lymphoma (cBCL) is a spontaneous cancer in dogs with similar pathologic features as human diffuse large B-cell lymphoma (DLBCL). The value of comparative oncology to both dogs and humans has long been recognized, but the progress in cBCL research has been hampered by a scarcity of preclinical models. This study aimed to establish and characterize novel patient-derived xenograft (PDX) and cell line models from primary cBCL tumors to address this critical gap. To this end, primary cBCL tumors from three canine patients were surgically excised and serially transplanted into immunodeficient NOD scid gamma (NSG) mice. The resulting PDX models were characterized across passages in mice using histology, flow cytometry, single-nucleotide polymorphism (SNP) genotyping, and RNA sequencing. The results show that the samples retain many of their original characteristics, even after multiple NSG passages. Cancer cells from two of the PDX lines were successfully adapted to in vitro culture, creating two new established cell lines which were then used in drug sensitivity assays. The successful generation and characterization of these cBCL PDX and cell lines provides a valuable resource for canine cancer research and associated comparative oncology approaches.
Open AccessEstablishment of Patient-Derived Xenotransplant and Cell Line Models for Canine B-Cell Lymphoma
High-grade canine B-cell lymphoma (cBCL) is a spontaneous cancer in dogs with similar pathologic features as human diffuse large B-cell lymphoma (DLBCL). The value of comparative oncology to both dogs and humans has long been recognized, but the progress in cBCL research has been hampered by a scarcity of preclinical models. This study aimed to establish and characterize novel patient-derived xenograft (PDX) and cell line models from primary cBCL tumors to address this critical gap. To this end, primary cBCL tumors from three canine patients were surgically excised and serially transplanted into immunodeficient NOD scid gamma (NSG) mice. The resulting PDX models were characterized across passages in mice using histology, flow cytometry, single-nucleotide polymorphism (SNP) genotyping, and RNA sequencing. The results show that the samples retain many of their original characteristics, even after multiple NSG passages. Cancer cells from two of the PDX lines were successfully adapted to in vitro culture, creating two new established cell lines which were then used in drug sensitivity assays. The successful generation and characterization of these cBCL PDX and cell lines provides a valuable resource for canine cancer research and associated comparative oncology approaches.
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Combined SpenLOF and Notch2GOF mutations induce formation of a non-canonical AiBC with MZB features.
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Combined SpenLOF and Notch2GOF mutations induce formation of a non-canonical AiBC with MZB features.
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Combined SpenLOF and Notch2GOF mutations lead to increased fitness of female AiBC.
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Combined SpenLOF and Notch2GOF mutations lead to increased fitness of female AiBC.
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Differentially Expressed Genes per cluster from multiome analysis
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Differentially Expressed Genes per cluster from multiome analysis
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Combined SpenLOF and Notch2GOF mutations drive an increase in AiBCs
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Combined SpenLOF and Notch2GOF mutations drive an increase in AiBCs
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
AIBC Signatures used in Fig. 6 H, K and L as well as S6K
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
AIBC Signatures used in Fig. 6 H, K and L as well as S6K
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Gene Overlap used in Fig. 6L and S6K
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Gene Overlap used in Fig. 6L and S6K
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
SpenLOF and Notch2GOF mutations skew mature B cells towards the MZB compartment
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
SpenLOF and Notch2GOF mutations skew mature B cells towards the MZB compartment
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Methods 1 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Containing Gating Strategies and Code
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Methods 1 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
Containing Gating Strategies and Code
- Open Access
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
SPENTRUNC mutations with loss of function effects are enriched in DLBCL.
- 12 August 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities
SPENTRUNC mutations with loss of function effects are enriched in DLBCL.